The online version of this article (doi:10.1186/1475-2875-11-325) contains supplementary material, which is available to authorized users.
Wiriya Rutvisuttinunt, Suwanna Chaorattanakawee contributed equally to this work.
The authors declare that they have no competing interests.
The views expressed in this article are those of the author(s) and do not reflect the official policy of the Department of the Army, Department of Defense, or the US Government. All human use research received the required ethical approvals from the appropriate authorities.
Study design: WR, KS, SDT. Conducted experiments, collected and analysed data: WR, SC, SDT, PT, KY, PC, YS, DB, CL, KS. Data interpretation, manuscript preparation: SC, PT, DSW, WR, DLS. Project oversight: SDT, MMF, KS, HN, DS and DLS. All authors read and approved the final manuscript.
Apparent emerging artemisinin-resistant Plasmodium falciparum malaria in Southeast Asia requires development of practical tools to monitor for resistant parasites. Although in vitro anti-malarial susceptibility tests are widely used, uncertainties remain regarding interpretation of P. falciparum field isolate values.
Performance parameters of the W2 P. falciparum clone (considered artemisinin “sensitive”) were evaluated as a reference for the HRP-2 immediate ex vivo assay. Variability in W2 IC50s was assessed, including intra- and inter-assay variability among and between technicians in multiple experiments, over five freeze-thaw cycles, over five months of continuous culture, and before and after transport of drug-coated plates to remote field sites. Nominal drug plate concentrations of artesunate (AS) and dihydroartemisinin (DHA) were verified by LC-MS analysis. Plasmodium falciparum field isolate IC50s for DHA from subjects in an artemisinin-resistant area in Cambodia were compared with W2 susceptibility.
Plate drug concentrations and day-to-day technical assay performance among technicians were important sources of variability for W2 IC50s within and between assays. Freeze-thaw cycles, long-term continuous culture, and transport to and from remote sites had less influence. Despite variability in W2 susceptibility, the median IC50s for DHA for Cambodian field isolates were higher (p <0.0001) than the W2 clone (3.9 nM), both for subjects with expected (less than 72 hours; 6.3 nM) and prolonged (greater or equal to 72 hours; 9.6 nM) parasite clearance times during treatment with artesunate monotherapy.
The W2 reference clone improved the interpretability of field isolate susceptibility from the immediate ex vivo HRP-2 assay from areas of artemisinin resistance. Methods to increase the reproducibility of plate coating may improve overall assay interpretability and utility.
Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM, Ariey F, Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwong M, Chotivanich K, Lim P, Herdman T, Sam An S, Yeung S, Singhasivanon P, Day NPJ, Lindegardh N, Socheat D, White NJ: Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009, 361: 455-467. 10.1056/NEJMoa0808859. PubMedCentralCrossRefPubMed
Noedl H, Attlmayr B, Wernsdorfer WH, Kollaritsch H, Miller RS: A histidine-rich protein 2-based malaria drug sensitivity assay for field use. AmJTrop Med Hyg. 2004, 71: 711-714.
Noedl H, Bronnert J, Yingyuen K, Attlmayr B, Kollaritsch H, Fukuda M: Simple histidine-rich protein 2 double-site sandwich enzyme-linked immunosorbent assay for use in malaria drug sensitivity testing. Antimicrob Agents Chemother. 2005, 49: 3575-3577. 10.1128/AAC.49.8.3575-3577.2005. PubMedCentralCrossRefPubMed
Petersen E: 3H-hypoxanthine incorporation into fresh and stored blood: implications for resistance determination in P. falciparum malaria. Ann Trop Med Parasitol. 1986, 80: 251-252. PubMed
Rason MA, Randriantsoa T, Andrianantenaina H, Ratsimbasoa A, Menard D: Performance and reliability of the SYBR Green I based assay for the routine monitoring of susceptibility of Plasmodium falciparum clinical isolates. Trans R Soc Trop Med Hyg. 2008, 102: 346-351. 10.1016/j.trstmh.2008.01.021. CrossRefPubMed
Bacon DJ, Latour C, Lucas C, Colina O, Ringwald P, Picot S: Comparison of a SYBR green I-based assay with a histidine-rich protein II enzyme-linked immunosorbent assay for in vitro antimalarial drug efficacy testing and application to clinical isolates. Antimicrob Agents Chemother. 2007, 51: 1172-1178. 10.1128/AAC.01313-06. PubMedCentralCrossRefPubMed
Akala HM, Eyase FL, Cheruiyot AC, Omondi AA, Ogutu BR, Waters NC, Johnson JD, Polhemus ME, Schnabel DC, Walsh DS: Antimalarial drug sensitivity profile of western Kenya Plasmodium falciparum field isolates determined by a SYBR Green I in vitro assay and molecular analysis. AmJTrop Med Hyg. 2011, 85: 34-41. CrossRef
Noedl H, Faiz MA, Yunus EB, Rahman MR, Hossain MA, Samad R, Miller RS, Pang LW, Wongsrichanalai C: Drug-resistant malaria in Bangladesh: an in vitro assessment. AmJTrop Med Hyg. 2003, 68: 140-142.
Noedl H, Se Y, Sriwichai S, Schaecher K, Teja-Isavadharm P, Smith B, Rutvisuttinunt W, Bethell D, Surasri S, Fukuda MM, Socheat D, Chan Thap L: Artemisinin resistance in Cambodia: a clinical trial designed to address an emerging problem in Southeast Asia. Clin Infect Dis. 2010, 51: e82-e89. 10.1086/657120. CrossRefPubMed
Bethell D, Se Y, Lon C, Tyner S, Saunders D, Sriwichai S, Darapiseth S, Teja-Isavadharm P, Khemawoot P, Schaecher K, Ruttvisutinunt W, Lin J, Kuntawungin W, Gosi P, Timmermans A, Smith B, Socheat D, Fukuda MM: Artesunate dose escalation for the treatment of uncomplicated malaria in a region of reported artemisinin resistance: a randomized clinical trial. PLoS One. 2011, 6: e19283-10.1371/journal.pone.0019283. PubMedCentralCrossRefPubMed
Teja-Isavadharm P, Siriyanonda D, Siripokasupkul R, Apinan R, Chanarat N, Lim A, Wannaying S, Saunders D, Fukuda MM, Miller RS, Weina PJ, Meléndez V: A simplified liquid chromatography-mass spectrometry assay for artesunate and dihydroartemisinin, its metabolite, in human plasma. Molecules. 2010, 15: 8747-8768. 10.3390/molecules15128747. CrossRefPubMed
Kaddouri H, Nakache S, Houze S, Mentre F, Le Bras J: Assessment of the drug susceptibility of Plasmodium falciparum clinical isolates from africa by using a Plasmodium lactate dehydrogenase immunodetection assay and an inhibitory maximum effect model for precise measurement of the 50-percent inhibitory concentration. Antimicrob Agents Chemother. 2006, 50: 3343-3349. 10.1128/AAC.00367-06. PubMedCentralCrossRefPubMed
Bell DR, Wilson DW, Martin LB: False-positive results of a Plasmodium falciparum histidine-rich protein 2-detecting malaria rapid diagnostic test due to high sensitivity in a community with fluctuating low parasite density. AmJTrop Med Hyg. 2005, 73: 199-203.
Wilson NO, Adjei AA, Anderson W, Baidoo S, Stiles JK: Detection of Plasmodium falciparum histidine-rich protein II in saliva of malaria patients. AmJTrop Med Hyg. 2008, 78: 733-735.
Tjitra E, Suprianto S, Dyer ME, Currie BJ, Anstey NM: Detection of histidine rich protein 2 and panmalarial ICT Malaria Pf/Pv test antigens after chloroquine treatment of uncomplicated falciparum malaria does not reliably predict treatment outcome in eastern Indonesia. AmJTrop Med Hyg. 2001, 65: 593-598.
Vossen MG, Pferschy S, Chiba P, Noedl H: The SYBR Green I malaria drug sensitivity assay: performance in low parasitemia samples. AmJTrop Med Hyg. 2010, 82: 398-401. CrossRef
Lim P, Wongsrichanalai C, Chim P, Khim N, Kim S, Chy S, Sem R, Nhem S, Yi P, Duong S, Mey Bouth D, Genton B, Beck H, Gobert JG, Rogers WO, Coppee JY, Fandeur T, Mercereau-Puijalon O, Ringwald P, Le Bras J, Ariey F: Decreased in vitro susceptibility of Plasmodium falciparum isolates to artesunate, mefloquine, chloroquine, and quinine in Cambodia from 2001 to 2007. Antimicrob Agents Chemother. 2010, 54: 2135-2142. 10.1128/AAC.01304-09. PubMedCentralCrossRefPubMed
- Optimizing the HRP-2 in vitro malaria drug susceptibility assay using a reference clone to improve comparisons of Plasmodium falciparum field isolates
Stuart D Tyner
Douglas S Walsh
David L Saunders
- BioMed Central
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II